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  Neonatal hypoxia-ischemia (HI) represents an intractable clinical condition that lacks an 
effective treatment and results in blindness, cerebral palsy, and cognitive deficits. A 
primary mechanism of cell death induced by neonatal HI is mitochondrial dysfunction 
leading to metabolic crisis and apoptosis. L-carnitine (LCAR) is an endogenous 
compound that transports fatty acids across the mitochondrial membrane for metabolism, 
buffers endogenous acyl-coA pools and improves the health and efficiency of the 
mitochondria. In light of the mitochondrial dysfunction observed after HI we 
hypothesized treatment with LCAR would reduce cell death after HI. Using a novel rat 
hippocampal slice culture model we observed a decrease in cell death in RHSC treated 
with 5mM LCAR for 2 hours prior to oxygen glucose deprivation (OGD). Under the 
same conditions we observed an LCAR induced decrease in both necrosis and 
mitochondrially-mediated apoptosis. To elucidate the mechanism for these data we 
studied the effect of LCAR on reactive oxygen species (ROS) before and after OGD. We 
observed a decrease in superoxide and H2O2 in RHSC treated with LCAR and exposed to 
OGD. In further experiments we observed LCAR treatment increased the expression and 
activity of superoxide dismutase 1 (SOD1) and catalase prior to OGD and this effect 
resulted in decreased cell death after OGD. In addition to increased (ROS) scavenging, 
we observed an LCAR mediated increase in levels of uncoupling protein 2 (UCP-2). In a 
series of experiments we observed a correlation between UCP-2 expression, the 
reversible modulation of mitochondrial membrane potential, and a decrease in cell death 
after OGD. These observations taken together suggest LCAR decreases cell death in 
RHSC after OGD by increasing ROS scavenging and UCP-2 expression in the 
mitochondria prior to OGD. 
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   Chapter 1 
 
INTRODUCTION 
 
1.1 Neonatal hypoxia ischemia 
 Neonatal hypoxic-ischemic encephalopathy (HIE) is a pathological condition 
caused by reduced cerebral blood flow that results in acute brain hypoxia ischemia (HI) 
[1-3]. Neonatal HIE occurs in approximately 1-6 per 1000 live births and results in 
significant neurodevelopmental disabilities in affected infants [4]. In the United States, 
severe (stage 3) HIE results in a mortality rate of 50-75% within the first month of life 
with up to 80% of survivors developing seizures, blindness, severe cognitive deficits and 
cerebral palsy characterized by hemiplegia, paraplegia, or quadriplegia [1, 5-9] [10].  
While severe HIE results in a high mortality/morbidity rate, the majority of 
neonates exposed to HI will develop moderate HIE that, while not fatal, will impair the 
cognitive and physical functioning of the individual throughout their lifespan.  Among 
infants who survive moderate HIE, 30-50% will suffer from serious complications and 
10-20% will experience minor neurological abnormalities that result in movement 
disorders, mild learning deficits and neurobehavioral alterations.[11-13] [1, 2, 10, 14, 15]. 
 In many cases the causative factors that induce HI remain idiopathic and therefore 
complicate rapid diagnosis and treatment. Currently, HIE has been linked to placental 
abruptio, cord accidents, traumatic compression lesions, congenital cyanotic heart 
disease, bacterial endocarditis, encephalitis, and coagulation irregularities due to 
deficiencies in protein C,S and anti-thrombin III [12]. While the causative agents 
involved vary, they all induce profound hypoxic-ischemic conditions (asphyxia, acidosis) 
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that result in acute or subacute brain injury leading to HIE in the neonate [12, 14, 15] [2, 
15].  
In the initial stages of neonatal HI, cerebral blood flow (CBF) is increased 
(irrespective of blood pressure) in a compensation response to decreased oxygen. If this 
adaptive response fails, the CBF becomes pressure-passive and is modulated directly by 
systemic blood pressure (BP). As BP drops, CBF falls below critical levels and glucose 
and oxygen levels continue to decrease leading to acute metabolic crisis. Simultaneously, 
brain temperature drops and GABA release increases in an attempt to minimize the initial 
effects of HI [16-18]. If the impairment of fetal oxygen and glucose persists over time it 
induces a cascade of molecular events that results in acidosis, inflammation, edema, and 
neuronal death resulting in lesions in the basal ganglia, hippocampus, cortex and 
subcortical white matter that are hallmarks of HIE [1, 7] [2, 19].  
The course of neonatal HI is characterized by a bi-phasic energy crisis in which 
the first phase of energy failure occurs during the ischemic event. During the second 
phase, cerebral metabolism briefly recovers only to deteriorate during reperfusion (6-24 
hours after initial injury) [2, 12, 20]. In the primary phase of energy failure oxygen 
sensitive neurons undergo calcium mediated necrosis. During the secondary phase of 
energy failure, widespread edema and apoptotic cell death occurs in the hippocampus and 
cortex lasting up to 72 hours following the initial insult[21, 22] [20, 23]. 
The neonatal brain is critically dependent on a steady supply of glucose and 
oxygen. When the brain is rendered ischemic, synaptic transmission ceases within 10-20 
seconds followed by an energetic failure of the Na+/K+ pump. Impairment of Na+/K+ 
pump allows the influx of sodium and water resulting in early stage cytotoxic edema. 
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Within 5-10 minutes cellular glucose is exhausted and intracellular lactate levels increase 
fivefold. After several hours the blood brain barrier is disrupted allowing an abnormal 
diffusion of nutrients leading to acidosis and white blood cell infiltration [1, 2, 9, 24-27]. 
Release of histamine, arachdonic acid, bradykinin, interleukins, and excitatory amino 
acids occur as a reactive response to hypoxia-ischemia and collectively induce vasogenic 
edema [26]. This effect coupled with acute lactic acidosis results in the denaturation of 
proteins and the inactivation of pH dependent enzymes [22, 26, 28].  
At a molecular level HI induces increases in glutamate and aspartate release in the 
cerebral cortex and basal ganglia. The release of excitatory amino acids activates NMDA, 
AMPA, and kainate receptors leading to sustained increases in intracellular and 
subcellular Ca++ levels that accumulate in the cytosol. Under basal conditions increased 
Ca++ release is countered by increased mitochondrial uptake to buffer polarization within 
the matrix. During HI, calcium buffering is rapidly overwhelmed inducing a spontaneous 
depolarization of the mitochondrial membrane that results in a massive, uncontrolled 
Ca++ efflux into the cytoplasm and the initiation apoptotic cell death [15, 25, 29, 30] [31, 
32]. 
 A secondary effect of excessive Ca++ buffering in the mitochondria is the 
activation of the mitochondrial permeability transition pore (MPTP). The MPTP is 
protein pore composed of adenine nucleotide translocase (ANT), voltage dependent anion 
channel (VDAC), the mitochondrial inner membrane transporter (Tim) and the 
mitochondrial outer membrane transporter (Tom). High levels of Ca++ or reactive oxygen 
species (ROS) induce permeability transition through the MPTP that results in an 
irreversible depolarization of mitochondrial membrane potential (MMP) and a loss of 
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ATP production through the cytochrome complex V in the electron transport chain (ETC) 
[31] [25]. The loss of ATP prevents the Na+/Ca+ exchanger from clearing excess calcium 
from the cell and triggers a cycle of Ca+ accumulation and ATP depletion that leads to 
necrosis and apoptosis [25] [20]. 
A direct effect of HI induced mitochondrial dysfunction is the increased 
production of reactive oxygen species (ROS; superoxide, hydrogen peroxide, 
peroxynitrite, and hydroxyl radical). HI disrupts cellular respiration and shunts energy 
from this process into the production of superoxide. Initially, superoxide dismutase 
(SOD) catalyzes the conversion of superoxide to hydrogen peroxide. As HI progresses 
the superoxide load increases rapidly, overwhelming basal SOD levels and allowing 
excess superoxide to scavenge lipid membranes, damage DNA and initiate apoptotic 
mechanisms [31, 33] [1, 20]. 
As SOD converts superoxide to hydrogen peroxide, glutathione peroxidase, 
catalase, and GSH reductase convert hydrogen peroxide to water. During HI the increase 
in hydrogen peroxide overwhelms enzymatic defenses resulting in an excess of hydrogen 
peroxide that can combine with Cu or Fe (Fenton reaction) and produce hydroxyl radical 
[20] [4]. The result of this dysfunction is cycle of damage in which ROS attack 
mitochondrial membranes destroying lipid integrity and increasing levels of toxic, 
oxidized fatty acids. As the ROS levels increase they perpetuate a cycle of damage that 
destroys ATP production, attacks DNA, and eventually scavenges cardiolipin allowing 
the release and translocation of cytochrome C leading to apoptosis[34, 35] [4] [31, 36] 
[20]. 
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1.2 The role of L-carnitine in the mitochondria 
A consequence of the HI induced mitochondrial dysfunction is the buildup of 
toxic acyl-CoA units, which, under basal conditions, is maintained in homeostasis by 
carnitine metabolism. Carnitine, a solubule molecule derived from dietary protein or 
synthesized in the liver and kidneys, facilitates the transport of long chain fatty acids 
from the cytosol across the mitochondrial matrix for metabolism via beta-oxidation and 
utilization in the citric acid cycle [37-39] . Three enzymes (carnitine palmitoyl transferase 
1, carnitine acylcarnitine translocase, and carnitine palmitoyl transferase 2) shuttle fatty 
acids into the mitochondria as long-chain fatty acylcarnitine esters.  Once inside the 
mitochondrial matrix carnitine removes toxic fatty acyl-CoA metabolites and 
supplements a pool of free CoA that is actively utilized to maintain acyl-CoA/free CoA 
homeostasis [40] [39]. 
However, during HI, mitochondrial dysfunction causes an accumulation of acyl-
CoA moieties that inhibit enzymes responsible for catalyzing glycolysis, 
gluconeogenesis, the citric acid and urea cycles, and fatty acid and protein catabolism 
[41] [27, 42-44].  To counter this effect researchers have added exogenous carnitine to 
cultured cells and noted a significant decrease in acyl-CoA moieties. Further studies in 
human trials have found exogenous carnitine treatment reduces acyl-CoA moieties in 
mitochondrial metabolic disorders and results in reduced mitochondrial dysfunction [9, 
38, 41, 42, 45-49]. 
The possible metabolic benefit of carnitine treatment was elucidated in work 
performed by Liu et al [50] and Ames et al [39] showing carnitine treatment improved 
ambulation and cognition in aged rats by increasing mitochondrial efficiency [50] [51] 
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 in vivo[38]. Further   studies by Al-Majed et al [52, 53] showed carnitine prevents the HI 
induced decrease in ATP production in neurons [52, 54]. 
To directly investigate the effect of carnitine during neonatal HI, Wainwright et al  
2003 administered carnitine to neonatal rat pups (IP injection; 30min prior to ligation), 
induced HI (unilateral carotid ligation followed by hypoxia) and observed significant 
decreases in infarct size at both 7 days and 28 days post HI. Furthermore, he noted L-
carnitine decreased neuronal death in both the cortex and hippocampus of animals 
subjected to HI suggesting the neuroprotective effect was not limited to a specific region 
of the brain [41]. 
 in vivoBased on his findings in the  model, Wainwright hypothesized the 
neuroprotection observed was due to carnitine mediated decreases in toxic acyl-CoA 
esters. While HI has been shown to increase acyl-CoA levels, it was unclear if carnitine 
treatment was reducing HI mediated damage by modulating this specific mechanism. In 
further studies, Wainwright observed a loss of neuroprotection and an increase in infarct 
size in animals administered carnitine after HI. This observation raised two specific 
questions about the acyl-CoA buffering hypothesis: 1.) if carnitine mediated acyl-CoA 
buffering decreased damage, why was this effect lost when treatment was given after HI? 
2.) Why does carnitine treatment after oxygen glucose deprivation (OGD) increase the 
damage from HI? While previous experimental observations do not directly refute the 
acyl-CoA buffering hypothesis, it does suggest the possibility of multiple neuroprotective 
mechanisms altered by carnitine treatment.    
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1.3 Overall Hypothesis and Aims 
 In light of Dr. Wainwright’s previous work and the unanswered questions 
discussed above, we undertook an in vitro study utilizing neonatal rat hippocampal slice 
cultures. The primary hypothesis we tested in this study was that L-carnitine would 
prevent cell death after OGD by decreasing mitochondrial dysfunction induced by 
oxygen glucose deprivation (OGD). To test this hypothesis the aims of this study were as 
follows: 
  
1.) Determine if carnitine reduces neuronal death in a hippocampal slice culture  
       model of OGD.  
  -If observed, measure the effect on OGD-induced necrosis and  
     apoptosis. 
  -Determine if carnitine preserves synaptic viability after OGD. 
  
2.) Determine if carnitine prevents mitochondrial dysfunction induced by OGD    
      by utilizing three separate parameters of mitochondrial health. 
  -Measurement of mitochondrial metabolic viability after OGD 
  -Elucidate the effect of carnitine treatment on ROS levels 
  -Measurement of mitochondrial membrane     
     potential (MMP) after OGD 
 
3.) If OGD-induced mitochondrial dysfunction is prevented by carnitine     
      treatment, delineate the mechanism(s) responsible. 
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Chapter 2 
 
MATERIALS AND METHODS 
 
2.1 Hippocampal Slice Preparation and Induction of Oxygen Glucose Deprivation: 
 Neonatal rats (Sprague-Dawley) at postnatal Day 7 (P7) were decapitated and the 
hippocampi dissected out under sterile conditions. The hippocampi were cut into 400μm 
slices on a McIlwain tissue chopper and individual slices were cultured on Millicell 
permeable membranes (0.4μM pore size) in six well plates for 6 days at 37o C in 5% CO2. 
For the first two days, the slices were maintained in a primary plating media (50% 
DMEM (+) glucose, 25% HBSS (+) glucose, 25% heat inactivated horse serum, 5 mg/mL 
D-glucose (Sigma), 1mM Glutamax, 1.5% PenStrep/Fungizone (Gibco), and 5 mL of 
50X B27 (Gibco) supplement plus anti-oxidants. On the fourth day in culture slices were 
placed in serum-free neurobasal medium (10mL Neurobasal-A, 200 μL of 50X B27 
supplement, 100 μL of 100X Fungizone, and 100 μL of 100X Glutamax). At 24h prior to 
experimentation (day 6), the inserts were placed in a serum-free neurobasal A media and 
B27 supplement without antioxidants.  Prior to the oxygen-glucose deprivation (OGD), a 
glucose free balanced salt solution (BSS) (120 mM NACl, 5mM KCl, 1.25 mM 
NaH PO , 2mM MgSO , 2mM CaCl , 25 mM NaHCO2 4 4 2 3, 20 mM HEPES, 25 mM sucrose 
pH of 7.3) was infused for 1h with 5% CO2/95% nitrogen at approximately 10L/h. 
Deoxygenated BSS was placed in a 6 well plate and warmed in a (Pro-Ox) chamber with 
an oxygen feedback sensor that maintained gas levels at 0.1% O2 for 15 minutes. The 
inserts were then transferred into deoxygenated BSS and placed back into the tank at 
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0.1% oxygen for 90 minutes. After this they were immediately transferred into 
prewarmed serum-free Neurobasal supplemented with B27 without antioxidants. 
 
2.2 Determination of Neuronal Population:  
 Representative brain slices were stained with NeuroTracer (Molecular Probes) to 
determine neuronal populations in hippocampal slices. Brain slices were fixed in 4o C 4% 
paraformaldehyde for 20 minutes, rinsed three times in PBS, removed from the Millicell 
inserts with a #5 paintbrush and placed on a glass slide. Slices were washed on the glass 
slide for 10 minutes in PBS plus 0.1% Triton X-100 to permeabilize membranes. 
NeuroTrace stain was diluted 1:20 in PBS and 200μl was placed on each individual slice 
for 20 minutes. After 20 minutes the stain was washed again with the Triton X-100 for 10 
minutes. The sections were then washed for 2 hours at room temperature and visualized 
on a Olympus IX51 fluorescent microscope at 506/529 ex/em using a 4X objective lens. 
Images were captured on a Hamamatsu camera using Image Pro Plus software.  
 
2.3 Measurement of Neuronal Death:  
 Propidium iodide (Molecular Probes) uptake was utilized to determine decreases 
in overall neuronal death associated with L-carnitine (LCAR) treatment prior to neonatal 
HI. Neonatal hippocampal brain slices were incubated with propidium iodide for 24 
hours at 100ng/ml washed 3 times with pre-warmed PBS without calcium or magnesium, 
and captured on an Olympus IX51 fluorescent microscope at 518/604 ex/em using a 4X 
objective lens. The fluorescent intensity was quantified in Image Pro Plus using IOD 
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(average density*area) measurement. All values obtained were normalized to the 
untreated control mean and expressed as a percent change. 
  
2.4 Measurement of Necrotic Death:  
 Lactate dehydrogenase was analyzed to determine if L-CAR treatment prevents 
HI-induced necrotic cell death. 24h post-OGD, 100μl of media was removed and assayed 
utilizing the CytoTox-ONE (Promega) assay kit to determine LDH release. The assay 
buffer and equilibrate substrate mix reagents were prepared according to manufacturers 
specified protocols. Maximal LDH release was determined by mechanically lysing 
untreated brain slices in 20μl of the manufacturer supplied Triton X-100 (9%) and 
measuring LDH release. Untreated hippocampal slices were utilized as a negative control 
and a blank well served as a vehicle control. Cell culture media was equilibrated to 22o C 
and 100μl of culture media was mixed with 100μl of CytoTox-ONE reagent in a 96 well 
plate and incubated at 22o C for 10min. After incubation 50μl of stop solution was added 
to each well, the plate was shaken gently for 10min and fluorescence read at 560/590 
ex/em. Protein content was determined by Bradford assay and all results were normalized 
for total protein. 
 
2.5 Measurement of Caspase Activation:  
 A caspase activation assay (Promega) was performed to determine if L-CAR 
decreased caspase activation after acute HI. 24h post-OGD brain slices were incubated 
with at 10uM assay reagent for 20min. Slices were washed  3 times with pre-warmed 
PBS without calcium or magnesium, and images captured on an Olympus IX51 
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fluorescent microscope at 506/529 ex/em using the 4X objective lens. The fluorescent 
intensity was quantified in Image Pro Plus using IOD (average density*area) function. 
All values obtained were normalized to the untreated control mean and expressed as a 
percent change. 
 
2.6 Measurement of Apoptotic Death:  
 Apoptotic neuronal death was measured by nick labeled DNA utilizing the 
TUNEL (Promega) assay. Slices were fixed in 4% paraformaldehyde for 20min at room 
temperature, rinsed in PBS three times and removed from Millicell inserts using a #5 
paintbrush. After removal slices were placed on glass slides and processed according to 
the manufacturer’s protocol. Images were captured at 506/529 ex/em and analyzed using 
ImagePro software. All values obtained were normalized to the untreated control mean 
and expressed as a percent change. 
 
2.7 Western Blot Analysis of Cleaved Caspase-9:  
 Rat hippocampal slices were harvested from inserts and pooled (4) in 200μl of 
SDS lysis buffer with 5% protease inhibitor cocktail (Sigma). Tissue was ground for 30 
seconds, sonicated for 5 seconds on ice water, and centerfuged at 14,000g at 4o C for 
10min. Protein content was determined by Bradford assay and 30-50μg of protein was 
prepared with Lamelli sample buffer and loaded into 10 well gels (Gradipore). The gels 
were transferred to PVDF membranes (Biorad Immun-Blot; 0.2μM pore size) for 90min, 
blocked in 5% non-fat dry milk and TBST for 1 hour, and incubated overnight on a roller 
at 4o with a cleaved caspase 9 anti-body at 1:1000 in 5% non-fat milk, (CC-9, Cell 
 11
Signaling). Blots were developed with a Femto kit (Pierce) and exposed for 10min (15 
captures) on a 440CF Kodak image station. Densitometry was performed using Kodak 
analysis software. Blots were stripped using Restore Western Blot Stripping buffer 
(Pierce), washed three times in TBST, and blocked for 1 hour in 5% non-fat dry milk and 
TBST. Blots were incubated overnight at 4o with a monoclonal antibody for β-actin 
(Sigma) and developed with a Femto kit (Pierce). All samples were normalized to β-actin 
values as a loading control prior to statistical analysis. All values obtained were 
normalized to the untreated control mean and expressed as a percent change. 
 
2.8 Measurement of Cytosolic Superoxide levels:  
 Cytosolic superoxide levels were determined by dihydroethidium DHE staining. 
Rat hippocampal slices were incubated with 20μM dihydoethidium (DHE) (Molecular 
Probes) for 20min, washed 3 times with pre-warmed PBS without calcium or magnesium, 
and captured on an Olympus IX51 fluorescent microscope at 518/604 ex/em using the 4X 
objective lens. The fluorescent intensity was quantified in Image Pro Plus using the IOD 
(average density*area) measurement. All values obtained were normalized to the 
untreated control mean and expressed as a percent change. 
 
2.9 Measurement of Mitochondrial Superoxide levels:  
 Mitochondrial superoxide levels were determined by MITOSOX staining. Rat 
hippocampal slices were incubated with 40μM MITOSOX (Molecular Probes) for 30min, 
washed 3 times with pre-warmed PBS without calcium or magnesium, and captured on an 
Olympus IX51 fluorescent microscope at 518/604 ex/em using the 4X objective lens. The 
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fluorescent intensity was quantified in Image Pro Plus using the IOD (average 
density*area) measurement. All values obtained were normalized to the untreated control 
mean and expressed as a percent change. 
 
2.10 Measurement of Hydrogen Peroxide levels:  
 Hydrogen peroxide levels were determined by DCF-DA staining. Rat 
hippocampal slices were incubated with 30μM DCF-DA (Molecular Probes) for 30min, 
washed 3 times with pre-warmed PBS without calcium or magnesium, and captured on an 
Olympus IX51 fluorescent microscope at 506/529 ex/em using the 4X objective lens. 
After image capture slices were washed 3 times in PBS without calcium and magnesium 
and re-incubated at 37o. The fluorescent intensity was quantified in Image Pro Plus using 
the IOD (average density*area) function. All values obtained were normalized to the 
untreated control mean and expressed as a percent change. 
 
2.11 Measurement of Superoxide Dismutase Activity:  
 SOD activity was measured using a WST-1 (tetrazolium salt) SOD assay kit 
(Dojindo Molecular Technologies). Rat hippocampal slices were treated for 2 hours, 
harvested using a #5 paintbrush and placed into buffer solution provided in the Dojindo 
kit with 5% protease inhibitor cocktail (Sigma). Samples were ground for 30 seconds, 
sonicated for 5 seconds on ice water, and centerfuged at 14,000g at 4o C for 10min. 
Protein content was determined by Bradford assay and used to normalize results. 
Specimens, controls, and standards were prepared according to the manufacturer’s 
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specified protocols. Absorbance at 450nm was recorded and SOD activity was calculated 
based on inhibition rate %. 
 
2.12 Measurement of Catalase Activity levels:  
 Rat hippocampal slices were harvested from inserts and pooled (4) in 200μl of 
SDS lysis buffer with 5% protease inhibitor cocktail (Sigma). Tissue was ground for 30 
seconds, sonicated for 5 seconds on ice water, and centerfuged at 14,000g at 4o C for 
10min. Protein content was determined by Bradford assay and 40μg of protein was added 
to 99μL of 0.05M potassium phosphate buffer (pH 7.0) Spectrophotometer was set at 
240nm and 25o C for 5 minutes and blanked in a quartz cuvette with phosphate solution 
and hydrogen peroxide. After blanking, 1μl of 3% H O2 2 was added to phosphate sample 
buffer and absorbance at 240nm was recorded at 10 second intervals for 60 seconds. The 
change in absorbance at 240nm was calculated and enzymatic activity determined 
according to methodology developed by Aebi, 1967.   
 
2.13 Estimation of Mitochondrial Metabolic Viability:  
 Viability of intracellular esterases was validated by Calcein Am staining. Rat 
hippocampal slices were incubated with 30μM Calcein AM (Molecular Probes) for 
30min, washed 3 times with pre-warmed PBS without calcium or magnesium, and 
captured on an Olympus IX51 fluorescent microscope at 506/529 ex/em using the 4X 
objective lens. After image capture slices were washed 3 times in PBS without calcium 
and magnesium and re-incubated at 37o. The fluorescent intensity of captured images was 
quantified in Image Pro Plus using the IOD (average density*area) function. All values 
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obtained were normalized to the untreated control mean and expressed as a percent 
change. 
 
2.14 Measurement of Mitochondrial Membrane Potential:  
 Measurement of mitochondrial membrane potential (MMP) over time was 
performed using Rhodamine 123 (Molecular Probes). Rhodamine 123 at 10μM was pre-
loaded 20min prior to image capture. Slices were washed 3 times with pre-warmed PBS 
without calcium or magnesium and visualized at an excitation/emission of 518/604. After 
image capture slices were washed 3 times in PBS without calcium and magnesium and 
re-incubated at 37o. The fluorescent intensity of images was quantified in Image Pro Plus 
using the IOD (average density*area) function. All values obtained were normalized to 
the untreated control mean and expressed as a percent change. 
 
2.15 Western Blot Analysis of SOD1, SOD2, Catalase, and UCP-2:  
 Rat hippocampal slices were harvested from inserts and pooled (4) in 200μl of 
SDS lysis buffer with 5% protease inhibitor cocktail (Sigma). Tissue was ground for 30 
seconds, sonicated for 5 seconds on ice water, and centerfuged at 14,000g at 4o C for 
10min. Protein content was determined by Bradford assay and 30-50μg of protein was 
prepared with Lamelli sample buffer and loaded into 10 well gels (Gradipore). The gels 
were transferred to PVDF membranes (Biorad Immun-Blot; 0.2μM pore size) for 90min, 
blocked in 5% non-fat dry milk and TBST for 1 hour, and incubated overnight on a roller 
at 4o with the primary anti-body (1:1000 5% non-fat milk, UCP-2, Sigma; SOD1, SOD2, 
Catalase, AbCam). Blots were developed with a Femto kit (Pierce) and exposed for 
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10min (15 captures) on a 440CF Kodak image station. Densitometry was performed 
using Kodak analysis software. Blots were stripped using Restore Western Blot Stripping 
buffer (Pierce), washed three times in TBST, and blocked for 1 hour in 5% non-fat dry 
milk and TBST. Blots were incubated overnight at 4o with a monoclonal antibody for β-
actin (Sigma) and developed with a Femto kit (Pierce). All samples were normalized to 
β-actin values as a loading control prior to statistical analysis. All values obtained were 
normalized to the untreated control mean and expressed as a percent change. 
 
2.16 Electrophysiology/ field recording:  
 Cultured slices on membrane were separated and placed in artificial cerebral 
spinal fluid (ACSF) containing (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2, 2.4 CaCl2, 1.2 
NaH Po , 11.4 glucose, and 21.4 NaHCO , saturated with 95% O  and 5% CO2 4 3 2 2 (pH 7.3), 
and maintained at 30° C. For recording, slices were transferred to a submersion type 
recording chamber constantly perfused (1.9 ml/min) with saturated ACSF at 30°C. Field 
excitatory post synaptic potentials (fEPSPs) were recorded using glass electrodes filled 
with HEPES buffered ACSF (pH 7.3) and induced by stimulating S. radiatum of CA1. 
Electrodes were placed in the area of CA1 with the most defined cell body layer.  If a 
response was not immediately achieved the electrodes were repositioned several times 
within CA1. fEPSPs were monitored at 0.05 Hz and were recorded using a Geneclamp 
500 amplifier (Axon Instruments) and AxographX (Version 1.0 release candidate 3.0, 
John Clements) or pClamp9 (Axon Instruments) recording software. All field recording 
experiments were performed by Dr. Matt Beckman and Greg Leary in the laboratory of 
Dr. Mike Kavanaugh at the University of Montana.  
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2.17 Statistical Analysis:  
 All data was analyzed utilizing Prizm software. One-way ANOVA with Tukey’s 
post-hoc was used to determine statistical significance between groups. Two-tailed, 
unpaired t-test was used to determine specific differences between single groups. A 
p<0.05 was considered significant and slices that were greater than +/- 4 standard 
deviations from the mean were considered outliers and omitted from statistical analyses. 
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Chapter 3 
 
RESULTS 
 
3.1 Effect of L-CAR on Cell Death after OGD 
 In previous studies by Wainwright et al [7], carnitine exerted a neuroprotective 
effect when administered prior to hypoxia-ischemia (HI). In vivo studies showed a 
significant decrease in infarct size in neonatal rats treated with carnitine prior to HI and 
an increased infarct size when administered after HI [41]. In an effort to elucidate the 
mechanism(s) responsible for Wainwright’s observations, we developed a reproducible 
oxygen glucose deprivation (OGD) model in neonatal rat hippocampal slice cultures 
(RHSC’s). Utilizing this model system we pre-treated cultures with carnitine, exposed 
them to OGD, and measured neuronal death. Our initial experiments in RHSC’s 
recapitulated Wainwright’s in vivo findings; pre-treatment with 5mM L-carnitine 2 hours 
prior to OGD significantly decreased neuronal death (as determined by propidium iodide 
staining), and administration of the same dose after OGD significantly increased neuronal 
death [fig.1a,b]. Furthermore, the pre-treatment effect was nullified when the carnitine 
was removed 12 hours prior to OGD suggesting treatment must occur within a short time 
frame prior to OGD to exert a neuroprotective effect [fig. 1].  
Our observations at 24 hours showed carnitine treatment prevented neuronal 
death after OGD. This finding, however, did not rule out the possibility that carnitine 
treatment merely delayed the onset of apoptotic cell death occurring after 24 hours. To 
determine if this effect was occurring we repeated carnitine treatments and measured PI 
uptake at 48 hours post-OGD. At 48 hours neuronal death did not significantly increase  
 
 18
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UT
D
OG
D
LC
AR
LC
AR
 P
RE
 O
GD
 
LC
AR
 W
AS
HO
UT
 O
GD
LC
AR
 P
OS
T O
GD
 
1
10
100
1000
10000
100000
Fig.1a Cell death measured by PI uptake 24
hours post OGD. RHSC treated with carntine
and exposed to 90 minutes of OGD showed
significantly less neuronal death when compared
to untreated OGD. Carnitine treatment after OGD resulted
in significantly increased neuronal death. Removing
carnitine 12 hours prior to OGD resulted in a loss of
neuroprotective effect. UTD= untreated control group.
*=p<0.05 all groups vs. UTD control; †=p<0.05 groups vs.
OGD.One-way ANOVA, Tukey's post-hoc. Bars represent 6
or more samples.
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Fig. 1b Representative images of RHSC showing propidium iodide staining 24 h post-
OGD. Panel A is untreated OGD, panel B LCAR treatment for 2 hours washed out for 12 
hours and exposed to 90 minutes of OGD, panel C is LCAR treated non-OGD, panel D is 
LCAR treatment after OGD, panel E is LCAR treatment prior to OGD, panel F is 
untreated non-OGD. Untreated OGD slices show a significant increase in cell death when 
compared to untreated non-OGD slices. The administration of L-CAR prior to OGD 
prevents cell death while administration after OGD increases cell death. All slices treated 
with L-CAR were treated at a concentration of 5mM for 2 hours; OGD exposures were 
90 minutes in duration. Images captured at 4x magnification. 
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Fig. 2a  Neuronal death measured by PI uptake
at 48 hours post OGD. RHSC treated with
carnitine showed decreased neuronal death at 48
hours when compared to untreated OGD. This
observation suggests LCAR prevents rather than
delays the onset of cell death after OGD.
UTD=untreated control. OGD is untreated RHSC
exposed to oxygen glucose deprivation. *=p<0.05
UTD vs all groups, One-way ANOVA, Tukey's post
hoc. Each bar represents a minimum of 4 samples.
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in the carnitine treated groups suggesting carnitine prevents rather than delays neuronal 
death from OGD [fig.2] From this observation we hypothesized carnitine would prevent 
the activation of at least one of the two primary mechanisms of neuronal death (necrosis 
and apoptosis) after OGD. [34] 
Based on the carnitine-mediated decrease in cell death, we studied the effect 
of carnitine on necrosis induced by OGD. Utilizing a lactate dehydrogenase (LDH) 
release assay we observed a significant decrease in necrotic death in carnitine treated 
RHSC’s. Furthermore this effect was observed at 2, 12, and 24 hours post-OGD 
indicating carnitine reduces necrosis throughout reperfusion [fig 3]. At 24 hours post-
OGD carnitine groups showed a significant increase in LDH release when compared to 
untreated controls but remained significantly less (p<0.05) than the untreated OGD 
group.  
 
3.2 The Effect of LCAR on Apoptosis after OGD 
 To begin studying the effect carnitine treatment on apoptotic death in RHSC we 
utilized a fluorescent assay for non-specific caspase activation. At 24 hours post-OGD we 
observed a carnitine mediated decrease in caspase activation when compared to untreated 
OGD groups [fig.4]. To further elucidate this effect we performed western blot analysis 
to measure levels of mitochondrial cleaved (activated) caspase 9 (CC-9) [fig. 5]. We 
observed a statistically significant, carnitine-mediated decrease in CC-9 levels, 
suggesting carnitine is reducing neuronal death by decreasing mitochondrially-mediated 
apoptosis. To ensure carnitine mediated decreases in caspase activation correlated with 
decreased  
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Fig. 3 Necrotic death in RHSC measured by LDH release.
At 2, 12, and 24 hours post-OGD untreated slices exposed
to OGD showed a significant increase in necrotic death.
Carntitine treated slices showed a significant decrease in necrotic
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Fig. 4a Caspase activation in RHSC after 24 hours of
OGD. Caspase activation was significantly increased in
both carnitine treated and untreated RHSC exposed to
OGD when compared to untreated non-OGD cultures.
Statistical analysis of untreated OGD and carnitine
treated OGD showed carnitine significantly decreased
caspase activation. *=p<0.05 all groups compared to
UTD control; One way ANOVA, Tukey's post-hoc. Bars
represent 6 or more samples.
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Fig. 4b Representative images of RHSC showing caspase activation at 24h post-OGD. 
Untreated RHSC exposed to OGD show a significant increase in non-specific caspase 
activation when compared to untreated, LCAR treated, and LCAR treated OGD exposed 
RHSC. Panel A is untreated OGD, panel B is untreated control, panel C is LCAR non-
OGD, panel D is LCAR OGD. OGD for 90min. LCAR at 5mM present for 2 hours prior 
to OGD. UTD is untreated control. OGD is untreated RHSC exposed to oxygen glucose 
deprivation. Images captured at 4x magnification. 
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Fig. 5b Representative images of Western blot analysis for cleaved caspase 9  
expression at 24hrs post-OGD. Images indicate LCAR treatment decreases  
the amount of cleaved caspase 9 protein after OGD. Also shown β-actin 
loading control. 
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apoptosis we performed the TUNEL assay on fixed hippocampal slices at 1, 6 and 24 
hours post-OGD. We observed a carnitine-mediated decrease in TUNEL positive  
neurons at 24 hours indicating carnitine pre-treatment reduces mitochondrially mediated 
apoptosis after OGD [fig. 6]. Based on our observation that carnitine pre-treatment 
reduced both necrosis and apoptosis we hypothesized the prevention of cell death would 
result in preservation of viable synaptic pathways within the hippocampus. To test this 
hypothesis we treated hippocampal slices with carnitine, exposed them to OGD, and then 
utilized field recording techniques to measure synaptic transmission. 
 
3.3 Synaptic Transmission in LCAR Treated Neurons after OGD 
 Measurement of synaptic transmission in RHSC’s following OGD (performed by 
the Kavanaugh laboratory) showed a significant decrease in EPSP amplitudes (<75uV; 
p<0.0001). In contrast, carnitine treated slices generated considerably more robust 
amplitudes (~300μV) after OGD and did not significantly differ from the untreated 
control at 48 hours [fig. 7]. These data suggest carnitine not only decreases neuronal 
death, but also prevents the OGD-induced loss of synaptic transmission.  
During acute HI, synaptic transmission ceases within 10-20 seconds and ATP 
reserves are depleted within 2-3 minutes [2]. After reperfusion synaptic transmission 
returns briefly only to decrease as the secondary phase of energy depletion occurs [20]. 
Previous studies by Kim et al (2006) showed a percentage of neurons exposed to mild HI 
will not undergo cell death, but are unable to generate functional EPSP’s due to acute 
mitochondrial dysfunction and ATP depletion [55] [34]. Based on these studies we 
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Panel C Panel D  
Fig. 6b Representative images of TUNEL stained RHSC at 24 hours post-OGD. Images 
show OGD increases the amount and intensity of TUNEL staining and LCAR treatment 
significantly decreases TUNEL staining suggesting LCAR reduces apoptotic cells. Panel 
A is untreated control, Panel B is LCAR treated, Panel C is OGD, and Panel D is LCAR 
treated OGD exposed. Images captured at 4x magnification. 
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Fig. 7a Representative traces of evoked EPSP’s in RHSC 48 hours after OGD. LCAR 
treated cultures exposed to OGD show a significantly larger EPSP when compared to 
untreated OGD cultures. This observation suggests LCAR prevents the OGD induced 
loss of synaptic transmission.   
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Fig. 7b Evoked EPSP’s in RHSC treated with carnitine and exposed to OGD. 
At 48 hours post-OGD carnitine treated cultures showed significantly greater 
evoked EPSP’s when compared to untreated OGD cultures. One way 
ANOVA, Tukey’s post hoc.  
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hypothesized the possibility of a link between carnitine treatment, preservation of 
synaptic viability, and the prevention of OGD-induced mitochondrial dysfunction leading 
to ATP depletion. This hypothesis was further reinforced by our finding that carnitine 
decreased mitochondrially mediated apoptosis which is directly linked to mitochondrial 
health. Based on these observations we elected to study the effect of carnitine on 
mitochondrial dysfunction induced by OGD. 
  
3.4 Metabolic Viability in LCAR treated RHSC exposed to OGD 
To begin measuring the effect of carnitine on mitochondrial health after OGD 
we stained RHSC with Calcein AM, a fluorogenic esterase substrate that is retained in 
neurons that are metabolically active. Utilizing this dye we measured the effect of 
mitochondrial metabolic viability in RHSC’s at 2, 6, 12, 24, and 48 hours after OGD. In 
untreated slices exposed to OGD we observed a rapid, irreversible decrease in metabolic 
activity (decreased fluorescence) that did not occur in the carnitine treated slices. At 6 
hours post-OGD carnitine treated slices showed a significant decrease in metabolic 
viability, but this effect reversed at 12, 24, and 48 hours with metabolic viability 
returning to basal levels at 48 hours post OGD [fig. 9]. Carnitine treatment alone resulted 
in an increase in calcein fluorescence suggesting carnitine not only prevents 
mitochondrial dysfunction but also increases metabolic viability prior to OGD.  
In light of this finding we elected to examine the effect of carnitine pre-
treatment on reactive oxygen species (ROS) which have been shown to disrupt membrane 
integrity after OGD leading to reduced metabolic viability and increased apoptosis.   
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Fig. 8a Metabolic viability in RHSC measured by calcein AM
fluorescence. Untreated RHSC exposed to OGD showed a loss
of metabolic activity at 6 hours post-OGD that remained
consistent through 48 hours post OGD. Carnitine treated
RHSC exposed to OGD showed a significant decrease in
metabolic viability at 6 hours, but this effect was reversed at 12
hours post-OGD. At 24 and 48 hours carnitine treated slices
exposed to OGD showed basal levels of metabolic activity.
*=p<0.05 all groups vs. UTD control; †=p<0.05 all groups vs
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Fig. 8b Representative images of RHSC stained with Calcein AM at 48 hours post OGD.  
Panel A is untreated OGD, panel B is LCAR non-OGD, panel C is LCAR OGD, panel D 
is UTD non-OGD. Images captured at 4x magnification. 
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3.5 Reactive oxygen species in LCAR treated RHSC exposed to OGD 
During OGD the majority of cellular ROS is produced within the 
mitochondrial matrix through complexes I-IV of the electron transport chain. The 
increase in ROS production creates a pathological cycle of membrane damage that 
depletes ATP. The loss of membrane integrity and ATP depletion further increases ROS 
eventually damaging DNA and resulting in the translocation of cytochrome c leading to 
mitochondrially mediated apoptosis. [20] [10, 31]. Based on our observation that 
carnitine prevents metabolic dysfunction and mitochondrially mediated apoptosis, we 
hypothesized carnitine treatment would achieve these effects by modulating superoxide 
produced by OGD exposure. 
 In previous studies performed by Ames et al (2004) carnitine treatment resulted in 
increased cellular respiration, and, as a byproduct, increased superoxide production. 
Utilizing RHSC treated with dihydroethidium (DHE) we also observed a significant, 
carnitine mediated increase in cytosolic superoxide that remained elevated at 4.5 hours of 
treatment. After 8 hours of treatment however, superoxide levels had significantly 
decreased and did not differ from the untreated controls. In RHSC’s pre-treated with 
carnitine and exposed to OGD, superoxide levels were significantly elevated at 1 and 6 
hours post-OGD. However, at 12 and 24 hours superoxide levels decreased and did not 
significantly differ from untreated controls [fig. 10, 11].  
 The carnitine-mediated decrease in superoxide levels at 12 and 24 hours was not 
observed when carnitine was administered after OGD suggesting it must be present prior 
to OGD to activate the mechanism(s) that modulate superoxide increases [fig. 12]. This  
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Fig. 9a Cytosolic superoxide in RHSC after 2
hours of carnitine treatment. Carnitine treatment
significantly increased superoxide levels. *=p<0.05,
Unpaired two-tailed T-test. Each bar represents a
minimum of 4 samples (each sample is composed
of 4 pooled slices).
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Fig. 9b Representative images of RHSC stained with DHE after 2h of LCAR treatment.  
Images indicate LCAR increases superoxide levels prior to OGD. Panel A UTD, panel B 
is LCAR treated. 
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Fig. 10a Cytosolic superoxide levels in RHSC
exposed to OGD. Carnitine treated slices
exposed to OGD showed superoxide levels at 6
and 12 hours that did not differ from untreated
OGD slices. At 12 and 24 hours post OGD
carnitine treated slices showed a significant
decrease in cytosolic superoxide. *=p<0.05 all
groups vs. UTD control; †=p<0.05 groups vs.
OGD, One way ANOVA, Tukey's post-hoc.
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Fig. 10b Representative images of RHSC stained with DHE at 12h post OGD.  Images 
show decreased superoxide staining after OGD in LCAR treated cultures when compared 
to OGD untreated groups. Panel A is untreated OGD, panel B is LCAR OGD, panel C is 
LCAR non-OGD, panel D is UTD control. Images captured at 4x magnification.
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Fig. 11a Cytosolic superoxide levels in RHSC at
24 hours post-OGD. Carnitine treatment prior
to OGD resulted in slices with significantly
decreased levels of superoxide. Addition of
carnitine after OGD resulted in superoxide levels
that did not differ from untreated OGD exposed
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One-way ANOVA, Tukey's post-hoc. Each bar
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Fig. 11b Representative images of RHSC stained with DHE at 24h post OGD.  Panel A 
UTD non-OGD, panel B is untreated OGD, panel C is LCAR non-OGD, panel D is 
LCAR post-OGD, panel E is LCAR pre-OGD. At 24 hours post-OGD, LCAR treatment 
decreased superoxide levels. Images captured at 4x magnification. 
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hypothesis is further supported by our finding that carnitine administration after OGD 
failed to protect neurons [fig. 1].  
 Mitochondrial superoxide levels measured by Mitosox assay correlated with 
cytosolic superoxide levels measured with DHE; carnitine treatment increasing 
mitochondrial superoxide prior to OGD and reducing mitochondrial superoxide at 24 
hours after OGD [fig. 13, 14]. Based on our observation that carnitine treatment post-
OGD failed to reduce superoxide levels and carnitine treatment prior to OGD increases 
superoxide, we hypothesized carnitine treatment was modulating superoxide levels after 
OGD by upregulating the expression of CuZn (cytosolic) superoxide dismutase (SOD1) 
and MnSOD (mitochondrial; SOD2) prior to OGD. This effect would increase superoxide 
scavenging capability and may account for the temporal decrease in superoxide observed 
in the carnitine treated groups. 
 
3.6 SOD protein levels and activity in LCAR treated RHSC exposed to OGD 
To test this hypothesis we treated RHSC’s with carnitine and performed 
Western blot analysis to evaluate expression levels of SOD1 and SOD2. After 2 hours of 
carnitine treatment SOD1 showed a significant increase in expression, while SOD2 
expression significantly decreased [fig. 15, 16].  Analysis of SOD1 expression at 2 hours 
post-OGD showed a significant increase in expression in carnitine-treated OGD slices, 
but at 24 hours post-OGD all experimental groups showed similar levels of SOD1 
expression. This finding, taken with our superoxide measurements, suggests RHSC’s 
exposed to OGD have increased amounts of superoxide present at 24 hours but do not 
 42
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Fig. 12a Mitochondrial superoxide in RHSC after
two hours of carnitine treatment. Carnitine
treatment significantly increased mitochondrial
superoxide prior to OGD. *=p<0.05, unpaired two
tailed T-test. Each bar represents a minimum of
4 samples; each sample is composed of 4
pooled slices.
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Fig. 12b Representative images of RHSC stained with MITOSOX after 2 hours of LCAR 
treatment.  Panel A is untreated control, panel B is LCAR treated. LCAR treatment 
increases mitochondrial superoxide. Images captured at 4x magnification. 
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Fig. 13a Mitochondrial superoxide in RHSC
24 hours after OGD.  Carnitine treated RHSC
showed a significant decrease in
mitochondrial superoxide 24 hours after
OGD. *=p<0.05, One way ANOVA, Tukey's
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Fig. 13b Representative images of RHSC stained with MITOSOX at 24h post OGD.  
LCAR treatment significantly reduces mitochondrial superoxide levels 24 hours after 
OGD. Panel A UTD OGD, panel B is LCAR non-OGD, panel C is untreated control, 
panel D is LCAR pre-OGD. Images captured at 4x magnification. 
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Fig. 14a Western blot analysis of SOD2
expression in RHSC after 2 hours of carnitine
treatment. Carnitine treatment resulted in a
significant decrease in SOD2 expression.
*=p<0.05, unpaired two tailed T-test. Each
bar represents a minimum of 5 samples;
each sample is composed of 4 pooled slices.
%
 o
f U
TD
 c
on
tr
ol
 
 
 
 
 
 
 
 
  
 46
 
 
 
UTD 
control
LCAR 
treated 
LCAR 
treated 
← 26 kDA
← 42 Kda β-actin 
UTD 
Control 
 
 
 
 
Fig. 14b Representative images of Western blot analysis showing  
SOD2 expression after two hours of LCAR treatment.  
Representative images show LCAR decreases SOD2 protein levels. 
Also shown β-actin loading control. 
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Fig. 15a Western blot analysis of SOD1 in RHSC
treated with carnitine for 2 hours. Carnitine treatment
resulted in a significant increase in SOD1
expression. *=p<0.05, unpaired two tailed T-test.
Each bar represents a minimum of 7 samples; each
sample is composed of 4 pooled slices.
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                       Fig. 15b Representative images of Western blot 
  analysis showing SOD1 expression after two  
  hours of LCAR treatment. LCAR treatment increases    
  SOD2 protein levels. Also shown β-actin loading control. 
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posses adequate levels of SOD1 protein to effectively convert it to H O2 2. In contrast, 
carnitine pre-treatment causes an increase superoxide which induces a corresponding 
increase in SOD1 expression, and this effect may ‘prime’ neurons for an acute oxidative 
stress similar to the insult OGD induces [fig. 17, 18].  
Based on this finding we elected to compare the effect of carntitine treatment 
on the enzymatic activity of SOD1 and determine if increased SOD1 expression 
correlated with increased enzymatic activity.  RHSC treated with carnitine for 2 hours 
were harvested and assayed for SOD activity. We observed a carnitine-mediated increase 
in SOD1 activity but did not observe a significant alteration in SOD2 activity, 
irrespective of the decreases in SOD2 expression [fig. 19]. This observation may be due 
to decreased enzymatic activity in untreated controls, increased activity in the LCAR 
treated cultures, or a combination of the two. The increase in mitochondrial superoxide 
and SOD1 expression and activity prior to OGD also suggests carnitine pretreatment may 
be generating superoxide in the mitochondria that is leading to increased SOD1 
expression and activity. 
To test this hypothesis we administered carnitine in the presence of a 
mitochondrially preferential anti-oxidant, lipoic acid (LA; antioxidant), and measured the 
effect on both mitochondrial and cytosolic superoxide levels. After determining LA 
treatment significantly reduces superoxide levels in hippocampal slices  [fig. 20, 21], we 
repeated the pre-treatments, exposed them to OGD, and measured cell death with 
propidium iodide uptake.  
The addition of lipoic acid in conjunction with carnitine treatment resulted in 
a significant loss of neuroprotection (p<0.05) [fig. 22] This observation suggests  
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Fig. 16a Western blot analysis of SOD1 in RHSC
2 hours post-OGD. Carntine treated RHSC showed
a significant increase in SOD1 expression 2 hours
post-OGD. Untreated slices exposed to OGD
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Fig. 17 Western blot analysis of SOD1 expression
in RHSC 24 hours post-OGD. No significant changes
were observed in slices at 24 hours. One way
ANOVA, each bar represents a minimum of 3
samples; each sample represents 4 pooled slices.
%
 o
f U
TD
 c
on
tr
ol
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 51
UTD TOTAL SOD LCAR TOTAL SOD
0
1
2
3
Fig. 18a Total SOD activity in RHSC after 2
hours of carnitine treatment. Carnitine treated
cultures showed a significant increase in
SOD1 activity. Carnitine treatment did not
significantly alter SOD2 activity. Unpaired, two
tailed T-test. Each bar represents a minimum
of 8 samples; each sample is composed of 4
pooled slices.
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Fig. 18b Cytosolic SOD (SOD1) activity in
RHSC after 2 hours of carnitine treatment.
Carnitine treated cultures showed a significant
increase in SOD1 activity. Unpaired, two tailed
T-test. Each bar represents a minimum of 8
samples; each sample is composed of 4
pooled slices.
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Fig. 18c Mitochondrial SOD (SOD2) activity in
RHSC after 2 hours of carnitine treatment.
Carnitine treatment did not significantly alter
SOD2 activity. Unpaired, two tailed T-test. Each
bar represents a minimum of 8 samples; each
sample represents 4 pooled slices.
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Fig. 19a Cytosolic superoxide in RHSC treated with
carnitine in the presence of lipoic acid (LA). LA
significantly reduced LCAR mediated increases in
cytosolic superoxide levels. *=p<0.05, LCAR vs.
groups One way ANOVA Tukey's post-hoc. Each
bar represents a minimum of 4 samples.
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Fig. 19b Representative images of RHSC stained with DHE to measure cytosolic 
superoxide levels after 2h of LA and LCAR treatment. LA effectively reduces the LCAR 
mediated increase in superoxide. Panel A is LA+LCAR, panel B is LCAR, panel C is 
LA, panel D is untreated control. Image captured at 4x magnification. 
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Fig. 20a Mitochondrial superoxide in RHSC
treated with carnitine in the presence of lipoic
acid (LA). LA significantly reduced LCAR mediated
increases in mitochondrial superoxide levels.
*=p<0.05 UTD vs. groups; †=p<0.05 LCAR vs.
groups. One way ANOVA, Tukey's post-hoc. Each
bar represents a minimum of 4 samples.
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Fig.20b Representative images of RHSC stained with MITOSOX to measure 
mitochondrial superoxide levels after 2h of LA and LCAR treatment. LA effectively 
reduces the LCAR mediated increase in mitochondrial superoxide. Panel A is LCAR, 
panel B is untreated control, panel C is LA, panel D is LCAR+LA. Images captured at 4x 
magnification, 
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Fig. 21a Propidium iodide uptake 24 hours post-OGD
in RHSC treated with carnitine and LA prior to and after
OGD. Carnitine pre-treatment in the presence of LA
resulted in a significant decrease in neuroprotection.
The addition of both LA and carnitine after OGD
significantly decreased neuronal death when compared
to carnitine post-OGD treatment. Addition of LA prior to
OGD failed to exert a neuroprotective effect while LA
treatment post OGD decreased neuronal death.
*=p<0.05 UTD vs. groups;  †=p<0.05 OGD vs. groups.
One way ANOVA, Tukey's post hoc. Each bar
represents a minimum of 4 samples.
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Fig. 21b Representative images of propidium iodide uptake in LA LCAR 
treated RHSC 24 hours after OGD.  The addition of LA reduces the protective effect of 
LCAR. Panel A is untreated control, panel B is LA post-OGD, panel C is LCAR pre-
OGD, panel D is LA LCAR pre OGD, panel E is untreated OGD. Images captured at 4x 
magnification. 
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carnitine-mediated neuroprotection is due, at least in part, to increases in ROS prior to 
OGD. This hypothesis is further supported by our finding that adding LA prior to OGD 
does not decrease neuronal death, but adding LA after OGD does confer significant 
neuroprotection. Based on these observations we hypothesized decreased ROS levels 
(due to LA-mediated ROS scavenging) prior to OGD resulted in decreased cellular 
antioxidant defenses and therefore made neurons vulnerable to ROS mediated damage. 
To test this hypothesis we added LA to RHSC’s and measured the effect on SOD1 and 
SOD2 expression levels.  
 
3.7 The Effect of an Anti-oxidant on LCAR Treatment 
 The addition of LA resulted in significant decreases in both SOD1 and SOD2 
expression when compared to the untreated control group [fig. 23, 24] (p<0.05). Carnitine 
treatment in the presence of LA nullified the increase in SOD1 expression suggesting 
SOD1 is modulated by carnitine-mediated increases in superoxide, and this observation 
may explain the increased neuronal death (propidium iodide uptake; fig. 22) observed in 
the experimental groups treated with LA (LA+LCAR, LA) prior to OGD.  
Taken together, these observations suggest carnitine is conferring neuroprotection 
by modulating superoxide levels leading to an increase in SOD1 expression and activity 
prior to OGD. This finding, however, does not entirely explain the decreased ROS levels 
measured after OGD. Previous work by Zemlyak et al [25] indicates AAV-mediated 
overexpression of SOD1 does not protect neurons against OGD [56]. However, 
overexpression of SOD1 in conjunction with catalase prior to OGD results in significant 
levels of neuroprotection [56]. This finding suggests the increase in SOD1 activity and 
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Fig. 22a Western blot analysis of SOD1 expression
after 2 hours of carnitine treatment in the presence or
absence of LA. LA significantly decreased SOD1
expression in carnitine treated RHSC. *=p<0.05 UTD
vs. groups; †=p<0.05 LCAR vs. groups. One way
ANOVA, Tukey's post-hoc. Each bar represents a
minimum of 3 samples; each sample is composed of 4
pooled slices.
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Fig. 23a Western blot analysis of SOD2 expression
after 2 hours of carnitine treatment in the presence or
absence of LA. LA significantly decreased SOD2
expression in untreated RHSC. LA treatment in the
presence of carnitine blocked the carnitine mediated
decrease in SOD2 expression. *=p<0.05 UTD vs.
groups. One way ANOVA, Tukey's post-hoc. Each
bar represents a minimum of 4 samples; each sample
represents 4 pooled slices.
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 expression may be coupled to increases in catalase, glutathione peroxidase, or GSH 
reductase to convert H O2 2 to water and avoid the formation of hydroxyl radical via the 
Fenton reaction. Based on Zemlyak’s previous studies of SOD1 and OGD, we 
hypothesized carnitine mediated neuroprotection was due to increases in both SOD1 
expression/activity and catalase expression/activity. To begin testing this hypothesis we 
measured H O  levels prior to and after OGD. 2 2
 
3.8 The Effect of LCAR on H O2 2 levels and Catalase Expression after OGD 
 Utilizing a membrane permeable fluorescent dye specific for H O2 2 (DCF-DA), we 
observed a significant increase in H O2 2 in the carnitine treated RHSC’s prior to OGD 
[fig.25]. At 2, 12, and 24 hours post-OGD H O2 2 was significantly decreased in the 
carnitine treated OGD group, but remained elevated in the OGD group [fig. 26]. This 
observation, combined with our data showing superoxide remains elevated for at least 6 
hours following OGD, suggests OGD results in a ‘superoxide bottleneck’ as SOD1  
converts physiologically large amounts of superoxide to H O . As H O2 2 2 2 is produced it is 
rapidly converted to water by carnitine-induced increases in catalase expression. To test 
this hypothesis we performed Western blot analysis to measure the effect of carnitine 
treatment on catalase expression prior to OGD.Western blot analysis showed carnitine 
treatment increases the expression of catalase prior to OGD [fig. 27]. This finding 
suggests catalase is playing a role in decreasing hydrogen peroxide levels after OGD. 
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Fig. 24a Hydrogen peroxide levels in RHSC
after 2 hours of carnitine treatment. Carnitine
treatment significantly increased hydrogen
peroxide. *=p<0.05 Unpaired two-tailed T-test.
Each bar represents a minimum of 12 samples.
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Fig 24b Representative images of DCF-DA staining in RHSC after 2h of LCAR 
treatment. LCAR increases H O2 2 after 2 hour of treatment. Panel A is untreated control, 
panel B is LCAR treated. Images captured at 4x magnification, 
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Fig. 25 H2O2 levels in RHSC treated with carnitine and
exposed to OGD. Carnitine treated cultures exposed to
OGD showed a significant decrease in H2O2 at 2, 12,
and 24 hours post OGD. Carnitine treatment in non-OGD
cultures showed a significant increase in H2O2 at 2 hours
post-OGD that gradually declined at 12 and 24 hours
post-OGD. *=p<0.05, One way ANOVA, Tukey's post-hoc.
Each bar represents a minimum of 3 samples.
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Fig. 25b Representative images of DCF-DA staining in RHSC after 2h of OGD. Panel A 
is untreated control, panel B is untreated OGD, panel C is LCAR pre-OGD, panel D is 
LCAR non-OGD.  Images captured at 4x magnification. 
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Fig. 25C Representative images of DCF-DA staining in RHSC after 24h of OGD.  LCAR 
treatment decreases H2O2 after OGD. Panel A is untreated control, panel B is untreated 
OGD, panel C is LCAR pre-OGD, panel D LCAR non-OGD. Images captured at 4x 
magnification. 
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Fig. 26a Western blot analysis of catalase
expression in RHSC after 2 hours of carnitine
treatment. Carnitine treatment resulted in a
significant increase in catalase expression.
*=p<0.05, unpaired two tailed T-test. Each bar
represents a minimum of 5 samples; each
sample is composed of 4 pooled slices.
%
 o
f U
TD
 c
on
tr
ol
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 70
 
 
 
 
 
 
 
 
UTD control LCAR treated UTD control 
← 60 kDa  
← 42 kDa β-actin 
LCAR treated 
     
 Fig. 26b Representative images of Western blot analysis showing catalase  
 expression after two hours of LCAR treatment. LCAR increases expression of  
 of catalase  Also shown β-actin loading control. 
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To further define this effect we measured catalase activity in carnitine treated slices and 
observed an increase in enzymatic activity when compared to untreated slices [fig. 28]. 
To determine if this effect was due to carnitine mediated increases in ROS we treated 
hippocampal slices with carnitine in the presence of LA and measured catalase 
expression and activity. 
Utilizing Western blot analysis and a catalase activity assay we observed a 
significant decrease in catalase expression and activity in the carnitine/LA treatment 
group [Fig. 28, 29] While it is not entirely possible to determine if this effect is due to LA 
scavenging superoxide, H O2 2 or both, it does suggest carnitine treatment is modulating 
catalase by increasing ROS prior to OGD.  
 While these observations indicate carnitine is exerting a neuroprotective effect by 
inducing a ROS mediated increase in SOD1 expression/ activity and catalase expression/ 
activity prior to OGD, they fail to explain why the addition of LA does not completely 
abolish the neuroprotective effect. Furthermore, the addition of LA with carnitine after 
OGD significantly reduced the level of cell death normally observed when carnitine was 
added after OGD. Comparing this observation with superoxide data obtained at 24 hours 
post-OGD, we noted the decrease in cell death was disproportionate with the level of 
superoxide (DHE) present when carnitine was added post-OGD.  
 In light of these two observations, it is possible multiple mechanisms are being 
actively modulated by carnitine treatment. Based on our previous observation that 
carnitine prevents metabolic dysfunction we elected to study MMP as a measurement of 
mitochondrial health and viability. We hypothesized carnitine treatment was preventing  
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Fig. 27 Catalase activity assay in RHSC treated with
carnitine in the presence or absence of LA. Carnitine
treated cultures showed a significant increase in
catalase activity when compared to untreated controls.
The addition of LA significantly reduced the
carnitine-mediated increase in catalase activity
indicating carnitine mediated increases in ROS
modulate catalase activity. One way ANOVA, Tukey's
post-hoc. *=p<0.05 LCAR vs. groups. Each bar
represents a minimum of 3 samples; each sample is
composed of 4 pooled slices.
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Fig. 28a Western blot analysis of catalase expression in
RHSC after 2 hours of carnitine treatment in the
presence or absence of LA. Carnitine treatment resulted
in a significant increase in catalase expression.
Treatment with LA in the presence of carnitine resulted
in a significant decrease in catalase expression
indicating carntine mediated increases in ROS modulate
catalase expression. One way ANOVA, Tukey's post-hoc
*=p<0.05 UTD vs. groups; †=p<0.05 LCAR vs. groups.
Each column represents a minimum of 4 samples; each
sample is composed of 4 pooled slices
**
*
† †
%
 o
f U
TD
 c
on
tr
ol
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 74
LCAR treated LCAR+LA LA treated
← 60 KdA
← 42 kDa β-actin
UTD control
 
Fig. 28b Representative images of Western blot analysis showing  
catalase expression after two hours of LCAR LA treatment. LA  
decreases the LCAR mediated increase in catalase expression.  
Also shown β-actin loading control. 
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metabolic dysfunction by blocking the irreversible depolarization of MMP induced by 
OGD. 
 
3.9 Measurement of MMP in LCAR treated RHSC exposed to OGD 
Utilizing Rhodamine 123 fluorescent staining, we measured mitochondrial 
membrane potential at 2, 6, 12, 24, and 48 hours post-OGD. At 2 hours post-OGD there 
was no significant difference in any of the OGD exposed groups, but in the carnitine 
treated cultures a significant increase in rhodamine staining was observed suggesting 
carnitine treatment may result in a significant hyperpolarizing effect. At 6, 12 and 24 
hours post-OGD we observed a significant MMP depolarization in untreated RHSC’s 
exposed to OGD with the majority of neurons depolarized (p<0.05) at 48 hours post-
OGD [fig. 31]. In contrast, carnitine treated slices exposed to OGD showed a significant 
MMP depolarization at 6 and 12 hours post-OGD, but showed a complete recovery (basal 
repolarization) of MMP at 48 hours post-OGD [fig. 31].  
In previous studies of mitochondria exposed to OGD, depolarization of MMP 
is an irreversible phenomenon due to the calcium or ROS mediated opening of the 
mitochondrial permeability transition pore (MPTP) [27]. However, based on our 
observations of MMP repolarization in the carnitine OGD slices, it appears unlikely that 
MMP modulation was due to the formation and activation of the MPTP pore. Current  
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Fig. 29a Mitochondrial membrane potential (MMP) in RHSC treated
with carnitine and exposed to OGD. Carnitine treatment in non-OGD
cultures resulted in a significant hyperpolarization at 2, 24, and 48
hours post-OGD. Carnitine treated cultures exposed to OGD showed a
significant depolarization at 12 hours post-OGD. At 24 and 48 hours
post-OGD MMP did not significantly differ from untreated, non-OGD
controls. Untreated RHSC exposed to OGD showed a mild
hyperpolarization at 2 hours post-OGD, however at 6, 12, 24, and 48
hours a significant MMP depolarization was observed. *=p<0.05 UTD
vs. groups; †=p<0.05 OGD vs. groups One way ANOVA,Tukey's
post-hoc. Each bar represents a minumum of 4 samples.
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Fig. 29b Representative images of Rhodamine 123 staining in RHSC after 48h of OGD.  
LCAR prevents the loss of MMP at 48 hours post-OGD. Panel A is untreated OGD, 
panel B is untreated control, panel C is LCAR non-OGD, panel D LCAR pre-OGD. 
Images captured at 4x magnification.  
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Fig. 30a Western blot analysis of UCP-2
expression in RHSC after 2 hours of carnitine
treatment. Carnitine treatment resulted in a
significant increase in UCP-2 expression.
*=p<0.05, unpaired two tailed T-test. Each bar
represents a minimum of 5 samples; each
sam
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 Fig. 30b Representative images of Western blot analysis showing  
 UCP-2 expression after two hours of LCAR treatment. LCAR treatment increases   
 UCP-2 protein levels. Also shown β-actin loading control.
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research indicates depolarization of MMP does not necessarily result in ATP depletion 
leading to neuronal death. In previous work by Mattiasson et al  [57] and Korde et al [58] 
application of a MMP uncoupler (2,4 DNP) showed mild depolarization prior to OGD 
(1hrs) resulted in significant decreases in ROS and neuronal death [57]. 
The induction of a mild, transient depolarization we observed in carnitine 
treated RHSC’s may be the product of a cellular mechanism designed to decrease ROS 
production. Combining this effect with the increased ROS scavenging we have observed 
with carnitine treatment may account for the rapid decrease in superoxide and H O2 2 
observed after OGD. In an effort to determine the possible mechanism responsible for the 
transient depolarization, we focused our attention on mitochondrial uncoupling proteins 
(UCP’s). 
Uncoupling proteins are pores within the inner mitochondrial membrane 
activated by superoxide in the presence of fatty acids or hydroxynoneals, a byproduct of 
oxidized fatty acids [59-62]. Once activated they decrease mitochondrial proton motive 
force by allowing protons to pass from the intermembrane space into the mitochondrial 
matrix effectively bypassing proton return through complex V (ATPase). While this 
effect decreases ATP production it also decreases concurrent ROS production from 
cellular respiration and allows ROS already produced within the mitochondria to 
translocate into the cytosol [57, 59, 60, 62-65]. The temporary disruption of ATP 
production also prevents the formation of the MPTP (ATP dependent) and decreases the 
glutamate induced calcium influx into the mitochondria by modulating MMP. The net 
effect of this activity is a reduction in MPTP activation, ROS production, and 
mitochondrially-mediated apoptosis [25, 66]. 
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Previous work by Mattison et al [57] showed over-expression of UCP-2 prior 
to hypoxia-ischemia exerted a neuroprotective effect [57]. Based on Mattison’s findings 
and the effect of carnitine treatment on MMP polarization, we hypothesized part of 
carnitine’s neuroprotective mechanism was an increase in UCP-2 expression prior to 
OGD. This effect would allow mitochondria greater control over MMP polarization and 
would also allow a significant amount of carnitine generated ROS to efflux from the 
mitochondria into the cytosol and thus protect mitochondrial membranes critical for 
metabolic viability. To begin testing this hypothesis we treated hippocampal slices with 
carnitine and measured UCP-2 expression levels. 
 
3.10 Measurement of UCP-2 protein in LCAR treated RHSC exposed to OGD 
After two hours of carnitine treatment, UCP-2 expression increased over 250% 
[fig. 32].  At 24 hours post-OGD the carnitine-mediated increase in UCP-2 expression 
was present in RHSC’s exposed to OGD as well as non-OGD controls. Exposure to OGD 
in untreated slices also increased UCP-2 expression at 24 hours [fig. 33]. Based on these 
observations and MMP polarization data, we hypothesized the increase in UCP-2 
expression in the untreated RHSC’s exposed to OGD did not result in a significant 
neuroprotective effect because it occurred after OGD. Increasing UCP-2 expression after 
a hypoxic-ischemic insult may be an adaptive response to increased superoxide levels 
that further increases mitochondrial dysfunction. Addition of the uncoupling effect of 
UCP-2 to MPTP activation may explain the severe irreversible depolarization observed in 
untreated RHSC’s exposed to OGD. In contrast, the increased expression of UCP-2 in  
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Fig. 31a Western blot analysis of UCP-2 expression in
carnitine treated RHSC exposed to OGD. Untreated
cultures exposed to OGD showed a significant increase
in UCP-2 expression at 24 hours post-OGD. *=p<0.05
UTD vs. groups. One way ANOVA, Tukey's post-hoc.
Each bar represents a minimum of 4 samples; each
sample is composed of 4 pooled slices.
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Fig. 31b Representative images of Western blot analysis showing  
UCP-2 expression 24h post OGD. OGD, LCAR treatment, and LCAR  
treatment prior to OGD all resulted in an increase in UCP-2 expression at  
24 hours post OGD. Also shown β-actin loading control.
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carnitine treated cultures prior to OGD would allow immediate activation to reversibly 
depolarize the MMP and avoid MPTP activation. To test this hypothesis we measured 
cell death (PI uptake) while pharmacologically blocking the activity of UCP-2 with 
guanosine diphosphate, (GDP) prior to and immediately after OGD and in the presence or 
absence of carnitine.  
 
3.11 Cell Death Following OGD in the Presence of UCP-2 Inhibition 
We observed a significant decrease in neuroprotection when carnitine was 
administered in the presence of UCP-2 inhibition (p<0.05; fig. 34). To further elucidate 
this effect we inhibited UCP-2 in the presence of carnitine, exposed them to OGD and 
measured an decrease in cell death when compared to UCP-2 inhibited RHSC’s exposed 
to OGD [fig. 34]. While these observations suggest carnitine is exerting a neuroprotective 
effect through UCP-2, they further suggest this effect is not solely responsible for the 
decreased cell death. 
In further studies we added carnitine prior to OGD and inhibited UCP-2 after 
OGD. Under these conditions we observed a significant increase in neuronal death when 
compared to RHSC’s treated with carnitine in the presence of UCP-2 inhibition. This 
finding suggests carnitine treatment reduces neuronal death by increasing UCP-2 prior to 
OGD and inhibition of increased UCP-2 expression after OGD results in greater cell 
death. This effect may be due to a loss of mitochondrial control over MMP uncoupling 
that result in increased superoxide production and MPTP activation. This hypothesis is 
further supported by our finding that inhibition of UCP-2 in the presence of carnitine 
prior to OGD resulted in decreased cell death. It is possible this effect is due to the  
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Fig. 32a Neuronal death in RHSC treated with
carnitine in the presence or absence of UCP-2
inhibiton. Carnitine treatment in the presence of
UCP-2 inhibition prior to OGD results in
decreased neuroprotection when compared to
carntine treatment alone. The addition of carnitine
in the presence of UCP-2 inhibition significantly
decreased neuronal death from OGD when
compared to UCP-2 inhibited cultures exposed to
OGD. *=p<0.05 UTD vs. groups, †=p<0.05 OGD
vs. groups, #=p<0.05 GDP OGD vs groups. One
way ANOVA, Tukey's post-hoc. Each bar
represents a minimum of 3 samples.
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Fig. 32b Neuronal death in RHSC treated with carnitine in
the presence or absence of UCP-2 inhibiton. Carnitine
treatment prior to OGD and UCP-2 inhibition after OGD
resulted in a significant increase in neuronal death when
compared to UCP-2 inhibited cultures treated with carnitine
prior to OGD. The addition of carnitine in the presence of
UCP-2 inhibition prior to OGD significantly decreased
neuronal death from OGD when compared to untreated
cultures exposed to OGD. *=p<0.05 UTD vs. groups,
†=p<0.05 OGD vs. groups, #=p<0.05  LCAR pre-OGD GDP
post-OGD vs. groups, +=p<0.05 GDP pre-OGD LCAR
post-OGD vs. groups. One way ANOVA, Tukey's post-hoc.
Each bar represents a minimum of 4 samples.
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 modulation of alternative mechanisms to compensate for the loss of UCP-2 function 
prior to OGD. 
 Previous studies by Mattiasson et al [57] demonstrated activation of UCP-
2 (by superoxide or hydroxynoneal) results in a mild, reversible depolarization of MMP 
that allows ROS to exit the mitochondria before damaging the inner mitochondrial 
membrane [57].Our observation that carnitine treatment increases UCP-2 expression may 
explain how mitochondria in carnitine treated cells rapidly shunt large amounts of 
superoxide into the cytosol. Based on previous data showing carnitine treatment increases 
cytosolic superoxide levels but decreases SOD2 expression, we hypothesized UCP-2 
activation was reducing mitochondrial superoxide after OGD by shunting superoxide into 
the cytosol. To test this hypothesis we inhibited UCP-2, treated with carnitine and 
measured mitochondrial superoxide levels to determine if UCP-2 was allowing carnitine-
generated superoxide to exit the mitochondria.  
 
3.12 The Effect of UCP-2 Inhibition on ROS Levels 
 Utilizing Mitosox fluorescent assay, we observed a significant increase in 
mitochondrial superoxide after 2 hours of UCP-2 inhibition (p<0.05) [fig. 35]. This effect 
was multiplied when carnitine was added in the presence of UCP-2 inhibition indicating 
UCP-2 is playing a significant role in decreasing carnitine-generated mitochondrial 
superoxide. This observation also suggests that under basal conditions UCP-2 may be 
playing a role in mild uncoupling to prevent excessive increases in superoxide as well as 
facilitating the efflux of superoxide into to the cytosol to protect lipid membranes and 
mtDNA. 
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Fig. 33a Mitochondrial superoxide in RHSC treated
with carnitine for 2 hours in the presence or absence
of UCP-2 inhibition. Carnitine treatment in the
presence of UCP-2 inhibition resulted in a significant
increase in mitochondrial superoxide. UCP-2 inhibition
of RHSC resulted in a significant increase in
mitochondrial superoxide when compared to
untreated control cultures. *=p<0.05 UTD vs. groups,
†=p<0.05 LCAR GDP vs. groups. One way ANOVA,
Tukey's post-hoc. Each bar represents a minimum of
6 samples.
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Fig. 33b Representative images of RHSC stained with MITOSOX after 2 hours of 
carnitine GDP treatment. Inhibition of UCP-2 in the presence of LCAR significantly 
increases mitochondrial superoxide. Panel A is untreated control, panel B is GDP, panel 
C is LCAR, panel D is GDP LCAR.
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 At 24 hours post-OGD we observed significantly lower levels of mitochondrial 
superoxide in carnitine-treated, OGD exposed RHSC’s when compared to UCP-2 
inhibited slices treated with carnitine and exposed to OGD (p<0.05) [fig. 36]. UCP-2 
inhibition prior to OGD resulted in a significant increase in mitochondrial superoxide 
when compared to OGD alone. This observation suggests UCP-2 significantly decreases 
mitochondrial superoxide in untreated, OGD exposed cultures. 
To further determine if UCP-2 was allowing the translocation of a significant 
amount of superoxide, we inhibited UCP-2 and then utilized DHE staining to measure 
cytosolic superoxide. Inhibition of UCP-2 resulted in a decrease in cytosolic superoxide 
24 hours after OGD [fig 37], and this effect was present both with and without carnitine 
treatment. The observation that UCP-2 inhibition prior to OGD significantly increases 
mitochondrial superoxide and decreases the presence of cytosolic superoxide suggests 
UCP-2 is shuttling superoxide out of the mitochondria after OGD. 
 UCP-2 inhibition in the presence of carnitine resulted in levels of cytosolic 
superoxide that did not significantly differ from carnitine treatment alone. This 
observation suggests carnitine may be modulating extra-mitochondrial mechanisms that 
generate superoxide. NADPH oxidase, xanthine oxidase, phospholipase A2 (PLA2), and 
oxidative metabolism of arachadonic acid have all been shown to generate superoxide 
that increase neuronal damage after hypoxia-ischemia [67, 68]. While the effect of OGD 
and carnitine on these mechanisms remains undefined, it is possible the increased 
superoxide levels we observed are due to enzymatic or PLA2 activation by carnitine 
treatment.  
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Fig. 34 Mitochondrial superoxide in RHSC treated
with carnitine in the presence or absence of UCP-2
inhibition. At 24 hours post-OGD, inhibition of UCP-2
in the presence of carnitine resulted in a significant
increase in mitochondrial superoxide. *=p<0.05 UTD
vs groups, †=p<0.05 OGD vs. groups, #=p<0.05
LCAR GDP vs. groups. One way ANOVA, Tukey's
post-hoc. Each bar represents a minimum of 5
samples.
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Fig. 35 Cytosolic superoxide in RHSC treated with
carnitine in the presence or absence of GDP. At 24
hours post-OGD, GDP treated cultures (with and
without carnitine) exposed to OGD showed a significant
decrease in cytosolic superoxide. *=p<0.05 UTD vs.
groups, †=p<0.05 OGD vs. groups. One way ANOVA,
Tukey's post-hoc. Each bar represents a minimum of 4
samples.
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 The hypothesis that UCP-2 activation decreases mitochondrial superoxide by 
shunting it into the cytosol may elucidate several undefined points in our collected data. 
Previous Western blot data shows carnitine treatment induces three key alterations: 
increased UCP-2 expression, decreased mitochondrial SOD (SOD2) expression, and 
increased cytosolic SOD (SOD1) expression. Previous work by Echtay [59] showed 
UCP-2 is activated by superoxide in the presence of fatty acids and inhibited by SOD 
[59]. From these findings we hypothesized the activation of UCP-2 results in a 
translocation of superoxide into the cytosol that stimulates increased expression of SOD1. 
 
3.13 UCP-2 Inhibition Alters SOD Expression in the Presence of LCAR 
 To begin testing this hypothesis we inhibited UCP-2, treated with carnitine and 
performed Western blot analysis for SOD1 and SOD2. We observed an increase in SOD2 
expression while inhibiting UCP-2 in the presence of carnitine [fig. 38]. This finding 
suggests inhibition of UCP2 blocks ROS efflux and results in increased SOD2 expression 
as a compensatory mechanism. Further support for this hypothesis is the decreased 
neuronal death observed when GDP is administered with carnitine prior to OGD, 
possibly due to increased SOD2 levels prior to OGD. Treating with carnitine prior to 
OGD and inhibiting UCP-2 post-OGD resulted in a significant increase in neuronal 
death, possibly because SOD2 levels are decreased and mitochondrial ROS cannot efflux 
into the cytosl through UCP-2.  
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Fig. 36a Western blot analysis of SOD2
expression after 2 hours of carnitine treatment
in the presence or absence of GDP. Inhibition of
UCP-2 decreased SOD2 expression, however,
UCP-2 inhibition in the presence of carnitine
significantly increased SOD2 expression.
*=p<0.05 LCAR GDP vs. groups One way
ANOVA, Tukey's post-hoc. Each bar represents
a minimum of 6 samples.
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  Fig. 36b Representative images of Western blot analysis showing 
  SOD2 expression after two hours of LCAR GDP treatment. Also  
  shown β-actin loading control. 
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Western blot analysis of SOD1 expression in carnitine treated, UCP-2 inhibited 
RHSC showed a significant increase in SOD1 expression [fig 39]. This finding suggests 
the possibility that UCP-2 is not solely responsible for shunting mitochondrial ROS into 
the cytosol. The inner mitochondrial membrane contains 35 anion carriers including 
adenine nucleotide translocase (ANT) which has been shown to exhibit molecular 
characteristics similar to UCP-2. In light of the carnitine/GDP-mediated increase in 
superoxide (~5500%) it is entirely possible that a unique (UCP-2 independent) anion 
carrier was activated allowing superoxide to efflux into the cytosol. To test this 
hypothesis we treated slices with carnitine, inhibited UCP-2 and measured cytosolic 
superoxide.  
Utilizing DHE staining we observed an increase in cytosolic superoxide after 
2 hours of UCP-2 inhibition (p<0.05) [fig 40]. The UCP-2 inhibition in carnitine treated 
RHSC resulted in a significant increase in cytosolic superoxide suggesting superoxide 
was shunted out of the mitochondria by UCP-2 independent mechanism(s). This 
observation is further supported by previous experimental data showing carnitine 
treatment in the presence of UCP-2 inhibition prior to OGD resulted in significantly 
decreased cell death when compared to RHSC that received carnitine prior to OGD and 
UCP-2 inhibition after OGD. Inhibition of UCP-2 function in the presence of carnitine  
 96
 
  
 
UTD GDP LCAR LCAR GDP
1
10
100
1000
Fig. 37a Western blot analysis of SOD1 expression
after 2 hours of carnitine treatment in the presence or
absence of GDP. Carnitine treatment in the presence
of UCP-2 inhibition significantly increased SOD1
expression. *=p<0.05 UTD vs. groups One way
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Fig. 37b Representative images of Western blot analysis showing SOD1  
expression after two hours of LCAR GDP treatment. Also shown β-actin  
loading control. 
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Fig. 38a Cytosolic superoxide in RHSC treated
with carnitine in the presence or absence of
GDP. Inhibition of UCP-2 in the presence of
carnitine significantly increased cytosolic
superoxide. *=p<0.05 UTD vs. groups; †=p<0.05
LCAR GDP vs. groups. One-way ANOVA,
Tukeys post-hoc. Each bar represents a
minimum of 7 samples.
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prior to OGD may induce alterations in secondary (UCP-2 independent mechanisms) 
mitochondrial proteins that compensate for the loss of UCP-2 function. Treating RHSC 
with carnitine prior to OGD and inhibiting UCP-2 after OGD ensures the cell cannot 
compensate for the loss of function prior to OGD.  
 
3.14 MMP in the Presence of UCP-2 Inhibition 
 To further test the hypothesis that UCP-2 independent mechanisms are activated 
when UCP-2 is inhibited prior to OGD we treated RHSC with carnitine, inhibited UCP-2, 
and measured MMP. Slices exposed to 2 hours of UCP-2 inhibition showed a significant 
MMP depolarization suggesting inhibition of basal levels of UCP-2 results in a 
spontaneous depolarization of MMP through an independent, unrelated mechanism(s). A 
significant hyperpolarizing effect was noted in RHSC treated with carnitine in the 
presence of UCP-2 inhibition [fig. 41]. This observation suggests UCP-2 activation 
modulates the hyperpolarizing effect of carnitine treatment and in turn this effect may 
further contribute to the increased UCP-2 expression we observed in carnitine treated 
RHSC.    
Rhodamine data in RHSC shows UCP-2 plays a role in modulating carnitine 
induced hyperpolarization of MMP. While it is possible increased UCP-2 expression may 
be a mitochondrial adaptation to hyperpolarized membrane potential, activation of UCP-2 
requires superoxide in the presence of fatty acids or hydroxynoneals (oxidized fatty 
acids). In previous studies we observed increases in superoxide, both prior to and after 
OGD, in carnitine treated RHSC. In light of this observation we hypothesized carnitine  
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Fig. 39a Mitochondrial membrane potential (MMP) in
RHSC treated with carnitine in the presence or absence
of GDP. Inhibition of UCP-2 resulted in a significant
MMP depolarization, however, inhibition of UCP-2 in the
presence of carnitine resulted in a MMP hyperpolarizing
effect. *=p<0.05 UTD vs. groups, †=p<0.05 LCAR vs.
groups. One-way ANOVA, Tukey's post-hoc. Each bar
represents a minimum of 5 samples.
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Fig 40a Western blot analysis of UCP-2
expression after 2 hours carnitine treatment in
the presence or absence of lipoic acid (LA).
Carnitine treatment in the presence of LA
significantly decreased UCP-2 expression.
*=p<0.05 UTD vs LCAR, †=p<0.05 LCAR vs.
groups One way ANOVA, Tukey's post-hoc. Each
bar represents a minimum of 4 samples; each
sample is composed of 4 pooled specimens.
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mediated superoxide was not only activating UCP-2, but also inducing increased 
expression levels prior to OGD. 
 
3.15 UCP-2 Protein Levels in the Presence of LCAR and an Anti-oxidant 
To test this hypothesis we treated slices with LCAR and an anti-oxidant (lipoic acid) and 
measured UCP-2 expression. Western blot analysis showed a LA-mediated decrease in 
UCP-2 expression. Carnitine treatment in the presence of LA resulted in a significant 
decrease in UCP-2 expression [fig. 42] indicating the carnitine mediated increase in 
UCP-2 is due, at least in part, to increased superoxide levels.  
To further study this effect, we treated slices with carnitine and GDP to induce 
increases in mitochondrial superoxide. Based on our previous study with anti-oxidant 
treatment in which we observed a decrease in UCP-2 expression we hypothesized 
increasing mitochondrial superoxide would result in a corresponding increase in UCP-2 
expression. To significantly increase mitochondrial superoxide in RHSC we treated with 
carnitine in the presence of UCP-2 inhibition. 
Inhibition of UCP-2 in the presence of carnitine resulted in a significant 
increase in UCP-2 expression [fig. 43]. While this finding does not rule out the possibility 
of an alternative mechanism compensating as a result of UCP-2 inhibition, it does suggest 
mitochondrial superoxide plays a role in modulating UCP-2 expression.  
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Fig 41a Western blot analysis of UCP-2 expression
after 2 hours carnitine treatment in the presence or
absence of GDP. Carnitine treatment in the presence
of UCP-2 inhibition significantly increased UCP-2
expression. *=p<0.05 UTD vs. groups, †=p<0.05 LCAR
vs. groups. One way ANOVA, Tukey's post-hoc. Each
bar represents a minimum of 3 samples; each sample
represents 4 pooled slices.
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Fig. 41b Representative images of Western blot analysis showing  
UCP-2 expression after 2h of LCAR GDP treatment. Also shown 
β-actin loading control. 
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Chapter 4 
DISCUSSION 
 
4.1   LCAR as a Treatment for HIE 
 Hypoxic ischemic encephalopathy (HIE) is a neurological disease that lacks an 
effective, standardized medical treatment. Currently the only protocol approved for the 
prevention of HIE is mild hypothermia. The CoolCap is hypothermic tool that reduces 
brain temperature (3-40 C) and must be employed prior to the secondary phase of energy 
failure that occurs 6-24 hours after the initial insult. Efficacy with this treatment is 
considered marginal with possible side effects (metabolic acidosis, leukocyte 
malfunctions, pulmonary hypertension, abnormal cardiac rhythm) occurring as a result of 
the rewarming process [2, 69].  
The utilization of emerging neuroprotective therapies for neonatal HI is hampered 
by two issues: potential toxicity/side effects and inefficacy when administered post HI. 
Carnitine treatment, when used as a standard protocol, may be a useful prophylactic 
treatment for neonatal stroke. Currrently, carnitine treatment is used in infants and 
children as a treatment for carnitine palmitoyl transferase II (CPTII) deficiencies and 
mitochondrial myopathies and encephalo-myopathies[40, 70, 71]. The compound can be 
administered easily, has no noted side effects, and can be given in high doses with 
extremely low toxicity [39, 47]. In light of these factors it would be possible to set up a 
dosing regimen several days prior to birth and, in cases of neonatal HI, for at least 72 
hours after the event. In addition to the stroke prevention this protocol could also serve as 
an immediate treatment for babies born with CPTII or carnitine deficiencies. The low 
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cost of carnitine (~20 cents for 500mg) and widespread availability make it a plausible 
treatment for expecting mothers in developing countries that do not have access to 
costlier hypothermic treatment and adequate follow up care.  
The purpose of this study was to elucidate the mechanism(s) of carntine mediated 
neuroprotection associated with acute hypoxia ischemia. Previous in vivo studies 
indicated caritine treatment prior to acute HI prevents neuronal cell death in the 
hippocampus. This observation was recapitulated in RHSC in our laboratory showing the 
in vivo effect correlated with our in-vitro model. Conversely, the addition of carnitine 
after OGD consistently resulted in a significant increase in cell death. These observations 
indicate the neuroprotective effect is due, at least in part, to alterations introduced prior to 
HI.   
Previous studies by Ames [39, 51, 75, 76] noted carnitine treatment increased 
ROS as an effect of increased cellular respiration and we observed this effect in our 
hippocampal slice culture model. Using DHE, Mitosox, and DCF-DA dyes, we observed 
a carnitine-mediated increase in ROS prior to OGD but a significant decrease in 
superoxide and hydrogen peroxide after OGD. The ability of carnitine-treated neurons to 
effectively decrease ROS after OGD indicates carnitine increases ROS scavenging 
ability. This finding, coupled with the observation that carnitine must be administered 
prior to HI, led us to hypothesize the possibility of a carnitine-induced ROS burst that 
alters neuronal scavenging capability prior to OGD.  
Supporting this hypothesis is data showing carnitine mediated increases in 
superoxide results in two specific mitochondrial effects: 1) decreased SOD2 expression 
and 2) increased UCP-2 expression. While decreasing SOD2 expression may appear 
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counterintuitive, previous work by Echtay [59] showed SOD directly inhibits UCP-2 
activity and this finding may explain our observation: decreasing SOD2 expression 
would allow an increase in UCP-2 activity. Based on our data showing anti-oxidant 
treatment significantly decreases UCP-2 expression, decreasing SOD2 would allow an 
increase superoxide leading to a corresponding increase in UCP-2 expression. 
 Furthermore, SOD activity assays showed RHSC treated with carnitine had SOD2 
activity levels that did not differ from untreated controls even though the expression of 
SOD2 in carnitine treated cultures was significantly decreased. This effect may be a due 
to several factors including a neuronal adaptation to maintain a basal scavenging rate 
while decreasing overall SOD2 expression. It may also be due to a decrease in active 
SOD2 protein in the controls while a greater percentage of the LCAR treated group 
maintains active SOD2. This would allow SOD2 to effectively dismutate any superoxide 
that fails to efflux into the cytosol while keeping expression levels low enough to allow 
increased expression and activation of UCP-2.  
 In turn, the mild activation of UCP-2 prevents carnitine induced hyperpolarization 
of MMP and ensures mitochondrial polarization remains within the optimal (~150mV) 
range to produce ATP through F1F0-ATPase and complex V. If cellular respiration 
increases rapidly (carnitine treatment) the inner mitochondrial membrane becomes 
hyperpolarized (>180mV) resulting in decreased ATP synthesis, increased calcium influx 
and elevated ROS production [25, 35, 72]. Our experimental data showing carnitine 
treatment in the presence of UCP-2 inhibition results in a significant MMP 
hyperpolarization indicates UCP-2 is modulating MMP during carnitine treatment. 
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UCP-2 activation in the presence of carnitine facilitates superoxide efflux from 
the mitochondria into the cytosol and induces, at least in part, increased expression of 
SOD1. This finding was further confirmed by inhibition of UCP-2 in conjunction with 
carntine treatment that resulted in increased mitochondrial superoxide and decreased 
cytosolic superoxide indicating UCP-2 translocates a significant amount of superoxide 
into the cytosol. As superoxide exits the mitochondria through UCP-2, increased levels of 
SOD1 convert it to H O . Excess H O2 2 2 2 is converted to water by catalase present in the 
cytosol. As carnitine induces increased H O2 2 from superoxide, catalase expression and 
activity increase as an adaptive response.  
  
 Oxygen glucose deprivation (OGD) in untreated neurons results in a rapid 
decrease in available glucose and oxygen resulting in acute ATP depletion and the 
accumulation of lactate. Simultaneously, excitatory amino acids glutamate and aspartate 
are released inducing excessive calcium influx into the neuron. As these two events 
occur, the mitochondria attempts to restore ATP production and buffer calcium influx. As 
OGD continues, ATP levels continue to decline rapidly resulting in energetic failure of 
the Na/K pump and the Na/Ca exchanger. The loss of Na/K regulation results in an 
uncontrolled influx of Na and H2O that induces cytoxic edema resulting in membrane 
damage [2, 26]. This effect is followed by a loss of Ca regulation that induces the 
formation and activation of the mitochondrial permeability transition pore resulting in a 
spontaneous, irreversible depolarization of MMP that cripples bioenergetic mechanisms 
and further depletes ATP[20]. 
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 In carnitine treated neurons, OGD results in increased mitochondrial superoxide. 
This effect, coupled with the possible increase of mitochondrial fatty acids (due to 
carnitine-mediated transport), could lead to increased activation of UCP-2. This effect, 
coupled with carnitine mediated increases in UCP-2, could result in a mild, reversible 
depolarization of MMP. The UCP-2 mediated depolarization would accomplish two 
tasks: 1) induce a decrease in protonmotive force thereby decreasing ROS production; 
and 2) prevent the formation and activation of the MPTP that results in irreversible 
depolarization of MMP. As ROS levels decrease over time UCP-2 activation ceases, 
MMP repolarizes to basal levels, and mitochondrial viability remains intact. 
 In untreated neurons, bioenergetic mechanisms begin to fail and energy from the 
electron transport chain and protonmotive force is shunted to produce ROS. As ROS 
levels increase they overwhelm cellular anti-oxidant defenses and scavenge lipid 
membranes resulting in toxic, oxidized fatty acids and a loss of mitochondrial structural 
integrity. As mitochondrial membranes disintegrate, oxidized cardiolipin releases 
cytochrome c from the inner membrane allowing it to translocate through the damaged 
mitochondria into the cytosol activating apaf-1 leading to caspase 3 activation and 
subsequent apoptosis. [12, 20, 31]  
 In contrast, carnitine treated neurons rapidly shuttle superoxide out of the 
mitochondria through increased UCP-2. Once in the cytosol, increased 
expression/activity of SOD1 converts large amounts of OGD generated superoxide to 
H O . Once in the cytosol H O2 2 2 2 is rapidly converted to water by increased 
expression/activity of catalase.  
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 Based on our observations carnitine treatment may play a role in treating long 
term neurodegenerative disorders that involve mitochondrial dysfunction and ROS 
production leading to cell death. Previous research by both Liu (2002) and Ames (2003) 
indicate carnitine may have clinical potential in delaying the cognitive decline associated 
with age or disease by improving mitochondrial efficiency [39, 50, 73-76]. 
 
4.2    LCAR Treatment in Neurodegenerative Disorders Involving Mitochondrial 
Dysfunction 
 Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the 
formation of Aβ plaques, neurofibrillary tangles, and profound neuronal loss. 
Biochemical analysis of CNS tissue from Alzheimer’s patients has shown abnormalities 
in cytochrome oxidase (COX) activity localized to the cerebral cortex and hippocampus. 
COX is the terminal enzyme in the electron transport chain responsible for catalyzing the 
transfer of electrons from ferrocytochrome c to molecular oxygen to form water. [77-80]. 
Studies in AD patients show mitochondrial expression of COX subunits II and IV are 
significantly lower due to increases in mutations (due to ROS damage) in mitochondrial 
DNA [81]. The end result of these mutations is reduced COX activity that results in 
decreased mitochondrial ATP production and increased in ROS [82, 83] [81, 84, 85]. 
 Utilization of carnitine might serve to alleviate this issue by increasing UCP-2 
expression and ROS scavenging ability, and could allow AD affected neurons to 
modulate MMP to quickly reduce damaging ROS levels. Carnitine treatment would also 
increase fatty acid transport into the mitochondria resulting in increased metabolic 
viability. In light of the increased cognition and ambulation Ames et al [39, 51, 75, 76, 
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86] noted when aged rats were treated with carnitine, it is not unrealistic to hypothesize 
the possible cognitive benefit of carnitine treatment in Alzheimers disease. 
 Another neurodegenerative disorder characterized by mitochondrial dysfunction 
is Parkinson’s disease (PD). While the causative agents for PD remains unknown it has 
been linked to reduced activity of complex I in the mitochondrial membrane. Further 
research has developed a novel model of PD that involves the infusion of rotenone, a 
mitochondrial complex I inhibitor. This technique results in the selective death of 
dopaminergic nerve terminals and causes retrograde degeneration of the substantia nigra 
that mimics PD pathology [87]. At the molecular level complex I inhibition results in 
depleted ATP, decreased Na+ /K+ ATPase activity and depolarized neurons. This in turn 
allows the activation of NMDA receptors (Mg plug removal) which induces an influx of 
calcium that the dysfunctional mitochondria fail to adequately buffer. The end result is 
calcium mediated activation of apoptosis leading to neuronal death [88]. 
 While it remains unknown if complex I dysfunction is an originating cause of PD 
or a symptom that contributes to disease progression, there is substantial research 
indicating PD dopaminergic neurons undergo mitochondrial dysfunction as a critical step 
in disease progression. Further studies have suggested complex I dysfunction is tied to 
ROS damage that occurs due to the age-related decrease in enymatic activity of ROS 
scavenging enzymes [89]. Currently, there is a growing body of research that directly 
links mitochondrially generated oxidative stress with the death of dopaminergic neurons 
within substantia nigra. In light of this finding, treatment of mitochondrial dysfunction 
may be a key target for therapeutic intervention.  
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 Based on our finding that carnitine decreases ROS production through modulation 
of MMP, increases ROS scavenging ability, and preserves metabolic viability suggest it 
may have clinical relevance as a treatment for patients suffering from PD. Since the 
compound has no known interactions, it may be possible to administer carnitine in high 
doses in conjunction with other drug therapies such as Levodopa and Carbidopa. 
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Chapter 5  
CONCLUSION 
 In this study we have evaluated the neuroprotective effect of carnitine on neonatal 
hippocampal slice cultures exposed to acute oxygen glucose deprivation (OGD). 
Working within this model system we have observed a significant decrease in cell death, 
both by mitochondrially-mediated apoptosis and necrosis, when carnitine is present prior 
to OGD. Carnitine treatment preserved synaptic and metabolic viability and prevented the 
OGD-induced irreversible loss of mitochondrial membrane potential by modulating 
uncoupling protein-2. In further studies we observed carnitine decreased reactive oxygen 
species by increasing the expression and activity of cytosolic superoxide dismutase and 
catalase. 
 As an endogenous compound with low toxicity, carnitine represents the 
possibility of a prophylactic treatment for neonatal stroke. In adult stroke patients, 
carnitine may have a role as a daily treatment for patients who are considered at-risk for 
secondary strokes. In light of the beneficial effect on mitochondrial health carnitine may 
have further applications in neurodegenerative diseases such as Alzheimers and 
Parkinson’s that involve mitochondrial dysfunction as a key aspect of the pathological 
process.  
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